Advancement in “Off-the-Shelf” CAR T-Cell Therapy for Cancer Immunotherapy

Abstract

The advent of chimeric antigen receptor (CAR) T cell therapies has revolutionized cancer treatment, especially in hematological malignancies. Despite the production costs, long production times, and inconsistent quality of personalized, autologous CAR T-cells have prompted a shift towards developing an off-the-shelf allogeneic option. This chapter reviews recent advancements and challenges in creating off-the-shelf CAR T-cell products, emphasizing donor selection, gene editing technologies, and production processes. Furthermore, the authors emphasize the potential advantages and challenges of this method, delineating future paths for research and clinical implementation.